Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 8/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.62 |
| ▸ | TP53 | P04637 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.53 |
| ▸ | GLA | P06280 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | CFTR | P13569 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | SCN1A | P35498 | 1/20 | 0.47 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18668786 | 0.95 | TSHR (0.65) | TSHRTDP1L3MBTL1CYP3A4MAPK1 | |
| Methyl Alcohol SCHEMBL27495118 | 0.91 | TSHR (0.70) | TSHRTDP1L3MBTL1CYP3A4MAPK1 | |
| SCHEMBL1513967 | 0.91 | TSHR (0.69) | TSHRTDP1L3MBTL1CYP3A4MAPK1 | |
| SCHEMBL896931 | 0.89 | TSHR (0.65) | TSHRTDP1L3MBTL1CYP3A4MAPK1 | |
| Dibutyl Phthalate SCHEMBL8088401 | 0.86 | TSHR (0.86) | TSHRTDP1L3MBTL1CYP3A4MAPK1 | |
| SCHEMBL27864832 | 0.86 | TSHR (0.72) | TSHRTDP1L3MBTL1CYP3A4MAPK1 | |
| SCHEMBL6057141 | 0.86 | TSHR (0.86) | TSHRTDP1L3MBTL1CYP3A4MAPK1 | |
| SCHEMBL31657765 | 0.85 | TSHR (0.70) | TSHRTDP1L3MBTL1CYP3A4MAPK1 | |
| SCHEMBL1308818 | 0.85 | TSHR (0.70) | TSHRTDP1L3MBTL1CYP3A4MAPK1 | |
| SCHEMBL7540618 | 0.85 | TSHR (0.87) | TSHRTDP1L3MBTL1CYP3A4MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 392 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3697389-B1 | SUSTAINED RELEASE FORMULATIONS OF CROCUS SATIVUS | COUNCIL SCIENT IND RES (IN) | 2025-08-20 | — | — | EP | claimed |
| US-20250242031-A1 | POLYMER SALTS FOR IMPROVED DRUG DELIVERY FROM AMORPHOUS SOLID DISPERSIONS | PURDUE RESEARCH FOUNDATION | 2025-07-31 | — | — | US | claimed |
| EP-4479092-A1 | POLYMER SALTS FOR IMPROVED DRUG DELIVERY FROM AMORPHOUS SOLID DISPERSIONS | Purdue Research Foundation (US) | 2024-12-25 | — | — | EP | claimed |
| WO-2023154171-A1 | POLYMER SALTS FOR IMPROVED DRUG DELIVERY FROM AMORPHOUS SOLID DISPERSIONS | PURDUE RESEARCH FOUNDATION (US) | 2023-08-17 | — | — | WO | claimed |
| CN-115777937-A | Diet-reducing capsule embedded with multi-element nutrient microspheres and preparation method thereof | 山东瑞安泰医疗技术有限公司 | 2023-03-14 | — | — | CN | claimed |
| US-20200390843-A1 | SUSTAINED RELEASE FORMULATIONS OF CROCUS SATIVUS | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2020-12-17 | — | — | US | claimed |
| US-10758490-B2 | Nanocapsules containing microemulsions | LIPOTEC, S.A. (ES) | 2020-09-01 | — | — | US | claimed |
| EP-3697389-A1 | SUSTAINED RELEASE FORMULATIONS OFCROCUS SATIVUS | Council of Scientific and Industrial Research (IN) | 2020-08-26 | — | — | EP | claimed |
| CN-110974945-A | Double-layer coated enteric lactase granule, preparation method and application thereof | 宁波希诺亚海洋生物科技有限公司 | 2020-04-10 | — | — | CN | claimed |
| CN-104783123-B | Prebiotics low sodium salt and preparation method thereof | 四川亿生元科技有限公司 | 2020-03-27 | — | — | CN | claimed |
| CN-1674877-A | Controlled release multiple unit drug delivery system | RANBAXY LAB LTD (IN) | 2005-09-28 | — | — | CN | claimed |
| WO-2005082330-A2 | CO-PRECIPITATED AMORPHOUS CEFDITOREN PIVOXIL AND DOSAGE FORMS COMPRISING THE SAME | RANBAXY LABORATORIES LIMITED (IN) | 2005-09-09 | — | — | WO | claimed |
| EP-1545473-A2 | MODIFIED RELEASE, MULTIPLE UNIT DRUG DELIVERY SYSTEMS | RANBAXY LABORATORIES, LTD. (IN) | 2005-06-29 | — | — | EP | claimed |
| WO-2003103637-A2 | MODIFIED RELEASE, MULTIPLE UNIT DRUG DELIVERY SYSTEMS | RANBAXY LABORATORIES LIMITED (IN) | 2003-12-18 | — | — | WO | claimed |
| EP-1185250-A2 | ENTERIC COATED PHARMACEUTICAL FORMULATION | NORTON HEALTHCARE LIMITED (GB) | 2002-03-13 | — | — | EP | claimed |
| EP-1119348-A2 | ENTERIC COATED PHARMACEUTICAL FORMULATION | NORTON HEALTHCARE LIMITED (GB) | 2001-08-01 | — | — | EP | claimed |
| WO-2001051031-A2 | ENTERIC COATED PHARMACEUTICAL FORMULATION | NORTON HEALTHCARE LTD. (GB) | 2001-07-19 | — | — | WO | claimed |
| WO-2000001363-A2 | ENTERIC COATED PHARMACEUTICAL FORMULATION | NORTON HEALTHCARE LTD. (GB) | 2000-01-13 | — | — | WO | claimed |
| CN-1126946-A | New pharmaceutical formulation | ASTRA AB (SE) | 1996-07-17 | — | — | CN | claimed |
| EP-0457919-A1 | FUNCTIONAL FOOD | KABUSHIKI KAISYA ADVANCE (JP) | 1991-11-27 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250242031-A1 | POLYMER SALTS FOR IMPROVED DRUG DELIVERY FROM AMORPHOUS SOLID DISPERSIONS | SRI, SYNGR2, PSD | TSHR 4586/4885TDP1 1627/4885L3MBTL1 4739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.